

March 12, 2026

**Attention: Certain U.S. Shareholders of ProQR Therapeutics N.V.**

**Re: ProQR Therapeutics N.V. and its subsidiaries PFIC Annual Information Statement**

Based on the average value of ProQR Therapeutics N.V. (the “Company”) and its subsidiaries gross assets and composition of income, the Company believes that the Company and its subsidiaries were not a PFIC for the 2025 taxable year. However, the status as a PFIC is a fact-intensive determination made on an annual basis, and the Company cannot provide any assurance regarding our PFIC status for the current, prior or future taxable years.

WE RECOMMEND U.S. SHAREHOLDERS CONSULT WITH THEIR TAX ADVISORS REGARDING ANY DECISION TO MAKE (OR REFRAIN FROM MAKING) ANY ELECTION THAT MAY BE AVAILABLE TO THEM BECAUSE ANY SUCH DECISION WILL DEPEND UPON THEIR OWN PARTICULAR TAX SITUATION AND MAY HAVE SIGNIFICANT AND CONTINUING U.S. TAX CONSEQUENCES. THE COMPANY IS UNABLE TO GIVE ADVICE IN THIS REGARD